ClinicalTrials.gg
TerminatedNCT04937166Updated Nov 10, 2025

A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies

A Phase 1 interventional study of DSP107 and Azacitidine in Acute Myeloid Leukemia, Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia, sponsored by Kahr Medical. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-10.

Sponsored by Kahr Medical · Phase 1, Interventional, and Treatment

Why this study was terminated
Slow enrolment

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States — 312 open to participants now, 466 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Enrollment
1,155th of 1,907
25 · median 35
Started
2022
with 80 others
Phase 1
772 of 2,137
130 open now
Registered
1,772nd of 2,137
by date

Among the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 1,155th largest by enrollment of the 1,907 interventional ones that give a count, is one of 81 that started in 2022, is one of 772 in phase 1, and was the 1,772nd registered.

Leukemia, Myeloid, Acute

3,668 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

312 of the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

307 more — sign in →

All 312 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

This study will be divided into two parts, Parts A and B and will enroll patients with relapsed/refractory AML or MDS/chronic myelomonocytic leukemia (CMML) patients who have failed up to 2 prior therapeutic regimens.

Part A is a dose escalation study to explore the safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) profile of DSP107 when administered in combination with azacitidine (AZA).

Part B is a dose escalation study to explore the safety, efficacy, PK and PD profile of DSP107 when administered in combination with AZA and venetoclax (VEN).

Read the detailed description

Part A is a dose escalation study in up to 4 cohorts of patients designed to test the safety and efficacy of DSP107 administered alone and in combination with AZA. The DSP107 starting dose level in Part A will be 0.3 mg/kg based on aggregate safety, PK and PD data from study DSP107_001, an ongoing study exploring the safety of escalating DSP107 doses in patients with advanced solid tumors. There will be a single DLT evaluation period, lasting 28 days, to determine the safety of DSP107 in combination with AZA. The safety, efficacy and PK data will be used to establish a recommended Phase II dose for potential future expansion cohorts and a starting dose for Part B.

Part B is a dose escalation study in 2 cohorts of patients that will test the safety and efficacy of DSP107 in combination with AZA and VEN. The starting dose for Part B will be at least one dose level lower than the DSP107 dose selected in Part A as being safe and effective in combination with AZA. Once a safe, effective dose has been established in Part B, a recommended phase 2 dose for patients with newly diagnosed AML will be agreed with the FDA at an End-of-Phase 1 meeting.

03

Conditions studied

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Chronic Myelomonocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) Performance Status 0-2
  • White Blood Cell count \< 20 x 10\^9/L.
  • Adequate organ function
  • AML or MDS/CMML patients who have failed up to 2 prior therapeutic regimens.

Exclusion criteria

Exclusion Criteria:

  • Acute Promyelocytic leukemia
  • Symptomatic central nervous system (CNS) leukemia or patients with poorly controlled CNS leukemia
  • Life-threatening (grade 4) immune-mediated adverse event related to prior immunotherapy
  • Immune-mediated adverse reaction that required discontinuation of prior immunotherapy
  • Past or current history of disease or immune deficiency
  • History of severe interstitial lung disease or severe pneumonitis or active pneumonitis
  • and poorly compensated liver disease
  • Prior organ allografts (such as renal transplant) requiring active
  • Active
  • Treatment with systemic immunostimulatory within 4 weeks prior to initiation of study treatment
  • Treatment with any 7/SIRPα targeting agent or immune agonists
  • Known allergy or to any of the test compounds, materials or to test product
  • Received live, attenuated vaccine within 4 weeks prior to first dose of study treatment
  • Active or C infection
  • History or evidence of any other clinically unstable/uncontrolled disorder, condition, or disease
  • Pregnant or breast feeding or planning to become pregnant while enrolled in the study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    DSP107 in combination with azacitidine or azacitidine plus venetoclax.

    DSP107 will be administered by intravenous infusion once weekly during each 28-day cycle to all patients in this study. Azacitidine (75 mg/m2/day) will be administered subcutaneously or intravenously for the first 7 days of every cycle. Patients enrolled in Part B only will also receive venetoclax. During Cycle 1, venetoclax will be dose escalated daily to the goal dose of 400 mg daily. Patients will receive 100 mg on Day 1, 200 mg on Day 2 and 400 mg on Day 3 and onwards.

    Biological: DSP107 · Drug: Azacitidine · Drug: Venetoclax

Interventions

  • BiologicalDSP107

    DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.

  • Azacitidine is an analog of the pyrimidine nucleoside cytidine.

    Also known as: Vidaza

  • Venetoclax is a B-cell lymphoma (BCL)-2 inhibitor

    Also known as: Venclexta, Venclyxto

06

What researchers measure

Primary outcomes

  1. Adverse Events (AEs)

    An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: Duration of the study, estimated to be 12 months

  2. Dose Limiting Toxicities (DLT)

    A DLT is defined as a clinically significant AE or laboratory abnormality that is related to DSP107 or the combination of DSP107 and AZA, but is unrelated to disease progression, intercurrent illness or concomitant medications

    Time frame: At the end of Treatment Cycle 2 (within 2 months of treatment initiation)

  3. Response Rate (RR) including Complete Remission (CR) and Complete Remission with Incomplete Blood Count Recovery (CRi)

    Response rates will be determined by assessing peripheral blood and bone marrow samples.

    Time frame: Within 6 months of treatment initiation

Secondary outcomes

  1. Overall Response Rate (ORR)

    Peripheral and bone marrow samples will be assessed to determine ORR. The ORR will measure the proportion of patients who achieve CR, CRi, complete remission with incomplete hematological recovery (CRh), complete remission with incomplete platelet recovery (CRp) or partial response (PR) within 6 months of treatment initiation, with or without cytogenetic response, hematological improvements and a morphologic leukemia-free state.

    Time frame: Within 6 months of treatment initiation

  2. Morphologic Leukemia-Free (MLF) Rate

    Peripheral and bone marrow samples will be assessed to determine the proportion of patients who are morphologically leukemia-free within 6 months of treatment initiation.

    Time frame: Within 6 months of treatment initiation

  3. Minimal Residual Disease (MRD) Status

    Peripheral and bone marrow samples will be assessed to determine minimal residual disease (MRD) status at response and/or the best MRD response during study participation.

    Time frame: Duration of the study, estimated to be 12 months

  4. 4-week Mortality Rate

    The proportion of patients who die within 4 weeks of treatment initiation.

    Time frame: Within 4 weeks of treatment initiation

  5. DSP107 Serum Concentration

    Serum samples will be collected to determine circulating levels of DSP107.

    Time frame: Duration of the study, estimated to be 12 months

  6. DSP107 anti-drug antibody (ADA) formation

    Serum samples will be collected throughout the study for assessment of ADA formation using validated assay.

    Time frame: Duration of the study, estimated to be 12 months

  7. Change in Phenotypic and Activation Profiles of Peripheral Blood Mononuclear Cells

    Whole blood samples will be collected throughout the study for immunophenotyping by flow cytometry and/or mass cytometry.

    Time frame: Duration of the study, estimated to be 12 months

07

Study locations

2 sites
  • City of Hope
    Duarte, California 91010, United States
  • The University of Texas MD Anderson Cancer Center, Department of Leukemia
    Houston, Texas 77030, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Apr 2025, 39 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2021
First posted
Jun 23, 2021
StartActual
Jan 13, 2022
Primary completionActual
Apr 23, 2025
CompletionActual
Oct 24, 2025
Last update
Nov 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04937166
Lead sponsor
Kahr Medical
Responsible party
Sponsor
First posted
Jun 23, 2021
Start date
Jan 13, 2022
Primary completion
Apr 23, 2025
Completion
Oct 24, 2025
Last update
Nov 10, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SIRPa-4-1BBL Fusion Protein DSP107

Start the discussion